Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. Amanda L. Jackson

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
University Of Cincinnati Physicians Company LLC
68 Cavalier Blvd, 
Florence, KY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Undifferentiated Pleomorphic Sarcoma
University Of Cincinnati Physicians Company LLC
68 Cavalier Blvd, 
Florence, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amanda Jackson is a Gynecologic Oncologist and an Oncologist in Florence, Kentucky. Dr. Jackson is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Intrauterine Device Insertion. Dr. Jackson is currently accepting new patients.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in RI
Hospital Affiliations
Christ Hospital
University Of Cincinnati Medical Center, LLC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
68 Cavalier Blvd, Florence, KY 41042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Enrollment Status: Recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation
Study Drugs: Bintrafusp Alfa, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin
Study Phase: Phase 1
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
View 8 Less Clinical Trials

43 Total Publications

Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Journal: Gynecologic oncology
Published: June 11, 2025
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Tahir Latif
Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Tahir Latif
Hematology | Oncology

University Of Cincinnati Physicians Company LLC

3188 Bellevue Ave, 
Cincinnati, OH 
 (10.5 miles away)
513-584-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tahir Latif is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Latif is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Roxana Aguirre-Pedroza
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Roxana Aguirre-Pedroza
Hematology Oncology | Hematology | Oncology

Kettering Independent Medical Group Inc

4441 Far Hills Ave, 
Kettering, OH 
 (52.9 miles away)
937-298-7751
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Roxana Aguirre-Pedroza is a Hematologist Oncology specialist and a Hematologist in Kettering, Ohio. Dr. Aguirre-Pedroza is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Her top areas of expertise are Gastrointestinal Stromal Tumor, Childhood Iron Deficiency Anemia, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma. Dr. Aguirre-Pedroza is currently accepting new patients.

Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Irfan Firdaus
Oncology
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Irfan Firdaus
Oncology

Christ Hospital Medical Specialists Ii, LLC

4460 Red Bank Expressway, Suite 200, 
Cincinnati, OH 
 (16.1 miles away)
513-321-4333
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Irfan Firdaus is an Oncologist in Cincinnati, Ohio. Dr. Firdaus is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Familial Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Firdaus is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jackson's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 23 Advanced Conditions
View All 56 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile